Power wheelchair — group 2 denied as duplicate or overlapping therapy by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## Why UnitedHealthcare Denies a Group 2 Power Wheelchair as Duplicate Therapy

A duplicate-therapy denial means UnitedHealthcare (UHC) has determined that you already have — or recently received — equipment that serves the same functional purpose as the requested Group 2 power wheelchair. This most commonly happens when there is an existing manual wheelchair, a lower-classification power wheelchair, or a scooter on record with the durable medical equipment (DME) supplier or insurer. Duplicate-therapy denials are often based on administrative record searches rather than a clinical assessment of whether the existing equipment actually meets your current functional needs.

## Why This Denial Is Appealable

A prior piece of equipment on record does not establish that it is clinically appropriate for your current condition. If your mobility impairment has progressed, if the prior equipment no longer provides adequate functional mobility, or if the prior equipment belongs to a different functional classification than a Group 2 power wheelchair, these are all grounds for overturning a duplicate-therapy denial. The clinical question is not "does any mobility equipment exist" but "does the existing equipment meet this patient's medically documented mobility needs."

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 (employer/commercial plans) or applicable state insurance law, you have the right to a full-and-fair internal review. File within the deadline printed on your denial notice.
• External review (ACA §2719): After a final internal denial, an independent IRO may review within approximately four months. IROs evaluate the clinical appropriateness determination, not just the administrative record.
• Expedited review: If your mobility limitation creates urgent health risk (e.g., inability to perform activities of daily living independently, pressure-injury risk from inadequate positioning), request expedited review at both levels.
• Medicare/Medicaid: If this is a Medicare Advantage or Medicaid managed-care plan, the CMS appeals framework applies in addition to or instead of ACA §2719 — follow the specific plan notice for the applicable track.

## Documentation to Gather

1. Current functional assessment: A face-to-face evaluation by a licensed physical or occupational therapist documenting your current mobility limitations, why existing equipment is inadequate, and the functional tasks you cannot perform with the equipment on record. 2. Equipment history: Documentation of when prior equipment was obtained, its classification, and its current functional adequacy (or inadequacy) for your needs. 3. Prescriber/specialist letter of medical necessity: From your physician or specialist, explaining why the Group 2 power wheelchair is medically necessary and why the prior equipment does not duplicate its function for your specific condition. 4. Diagnosis and progression documentation: Chart notes establishing your mobility-limiting diagnosis, any progression of the condition, and current clinical status.

## Criteria-Mapping Structure

Obtain UHC's DME coverage policy for Group 2 power wheelchairs and its duplicate-therapy criteria. Map each element:

| UHC Criterion | Your Evidence | |---|---| | Prior equipment on record | [Equipment type, acquisition date, classification] | | Prior equipment is functionally inadequate | [Therapist assessment, functional limitations documented] | | Current equipment is a different functional classification | [Group 2 vs. prior equipment classification distinction] | | Medical necessity of Group 2 specifically | [Prescriber letter, functional assessment, diagnosis] |

The therapist's functional mobility assessment is typically the most dispositive document in a duplicate-therapy DME appeal.